31 results on '"Sineshaw, Helmneh M"'
Search Results
2. County-Level Variations in Receipt of Surgery for Early-Stage Non-small Cell Lung Cancer in the United States
- Author
-
Sineshaw, Helmneh M., Sahar, Liora, Osarogiagbon, Raymond U., Flanders, W. Dana, Yabroff, K. Robin, and Jemal, Ahmedin
- Published
- 2020
- Full Text
- View/download PDF
3. Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy.
- Author
-
Sineshaw, Helmneh M., Zettler, Christina M., Prescott, Jennifer, Garg, Mahek, Chakraborty, Samhita, Sarpong, Eric M., Bai, Claire, Belli, Andrew J., Fernandes, Laura L., and Wang, Ching‐Kun
- Subjects
- *
DIFFUSE large B-cell lymphomas , *TREATMENT effectiveness , *STEM cell transplantation , *CHIMERIC antigen receptors - Abstract
Background: Although initial treatment of diffuse large B‐cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contemporary data on characteristics, treatment patterns, and outcomes for R/R‐DLBCL. Methods: Patients with incident (January 2016 to March 2021) DLBCL age ≥18 years who initiated first‐line (1L) therapy were identified from the COTA real‐world database. Baseline characteristics, treatment patterns, and real‐world outcomes, including time to next treatment (rwTTNT) and overall survival (rwOS), were assessed for the study population and by line of therapy (LOT). Results: A total of 1347 eligible DLBCL patients were identified. Of these, 340 (25.2%) proceeded to receive 2L, of whom 141 (41.5%) proceeded to receive 3L, of whom 51 (36.2%) proceeded to receive 4L+. Most common treatments were R‐CHOP in 1L (63.6%), stem cell transplant (SCT) in 2L (17.9%), polatuzumab vedotin, bendamustine, and rituximab (Pola‐BR) in 3L (9.9%), and chimeric antigen receptor T‐cell therapy (CAR‐T) in 4L (11.8%). Treatment patterns were more variable in later LOTs. One‐ and 3‐year rwOS from 1L initiation were 88.5% and 78.4%, respectively. Patients who received later LOTs experienced numerically lower 1‐ and 3‐year rwOS (from 2L initiation: 62.4% and 46.4%, respectively). Conclusions: In this real‐world analysis, 25.2% of patients experienced R/R‐DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer
- Author
-
Sineshaw, Helmneh M., Ng, Kimmie, Flanders, W. Dana, Brawley, Otis W., and Jemal, Ahmedin
- Published
- 2018
- Full Text
- View/download PDF
5. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt
- Author
-
Dominici, Laura S., Sineshaw, Helmneh M., Jemal, Ahmedin, Lin, Chun Chieh, King, Tari A., and Freedman, Rachel A.
- Published
- 2017
- Full Text
- View/download PDF
6. Treatment Patterns Among Women Diagnosed With Stage I-III Triple-negative Breast Cancer
- Author
-
Sineshaw, Helmneh M., Freedman, Rachel A., DeSantis, Carol E., and Jemal, Ahmedin
- Published
- 2018
- Full Text
- View/download PDF
7. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States
- Author
-
Sineshaw, Helmneh M., Robbins, Anthony S., and Jemal, Ahmedin
- Published
- 2014
8. Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting.
- Author
-
Gautam, Santosh, Yeola, Shweta, Nahar, Akash, Sarpong, Eric M, Prescott, Jennifer, Yang, Xiaoqin, and Sineshaw, Helmneh M
- Abstract
Aim: Unfavorable prognostic factors among classical Hodgkin lymphoma (cHL) patients in the real-world setting have yet to be fully characterized. Methods: In this retrospective study using the ConcertAI Oncology Dataset, patient characteristics, unfavorable prognostic factors and treatment patterns were evaluated among patients diagnosed with cHL. Results: Among 324 adult cHL patients diagnosed 2016–2021, 16.1% were classified as early favorable, 32.7% early unfavorable and 51.2% advanced disease. Early unfavorable patients were younger and had a larger nodal mass. The prognostic factor B symptoms was most frequently documented in early unfavorable patients (59.4%), followed by bulky disease (46.2%), >3 involved lymph node regions (31.1%), and erythrocyte sedimentation rate ≥50 (25.5%). Conclusion: In this analysis of real-world data, we found that nearly a third of newly diagnosed cHL patients had early unfavorable disease. Our analysis also showed differences in the proportion of patients for each unfavorable factor among patients with early-stage unfavorable cHL. Lymphoma is a type of blood cancer that develops when white blood cells grow out of control. This study looked at a certain type of lymphoma called classical Hodgkin lymphoma (cHL). Patients with cHL are put into groups based on risk factors. Risk factors mean the cancer had certain characteristics that make it more likely to spread to other body parts and more difficult to treat. These can be symptoms like drenching night sweats, unexplained fever, sudden weight loss, or large swellings of the infection fighting glands of the body.What did we do? We studied the risk factors of patients with cHL, using data from electronic medical records. What were the results? About a third of the patients in this study had early stage cHL with unfavorable risk factors, and over half of the patients had advanced stage cHL. The patients who had early stage cHL with unfavorable risk factors were younger and had a larger lump in a lymph node. More than half of the patients experienced drenching night sweats, unexplained fever, or weight loss of more than 10%. What do the results mean? We found that nearly a third of new cHL patients had early-stage cHL with unfavorable risk factors. We also showed differences in the number of patients with each unfavorable risk factor among patients with early-stage unfavorable cHL. This study can help doctors and researchers group patients and determine the best treatment or research study for patients who have cHL. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Factors associated with radiation therapy incompletion for patients with early-stage breast cancer
- Author
-
Freedman, Rachel A., Fedewa, Stacey A., Punglia, Rinaa S., Lin, Chun Chieh, Ward, Elizabeth M., Jemal, Ahmedin, and Sineshaw, Helmneh M.
- Published
- 2016
- Full Text
- View/download PDF
10. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011)
- Author
-
Sineshaw, Helmneh M., Gaudet, Mia, Ward, Elizabeth M., Flanders, W. Dana, Desantis, Carol, Lin, Chun Chieh, and Jemal, Ahmedin
- Published
- 2014
- Full Text
- View/download PDF
11. Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State
- Author
-
Sineshaw, Helmneh M., Wu, Xiao-Cheng, Flanders, Dana W., Osarogiagbon, Raymond Uyiosa, and Jemal, Ahmedin
- Published
- 2016
- Full Text
- View/download PDF
12. State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States.
- Author
-
Fedewa, Stacey A, Kazerooni, Ella A, Studts, Jamie L, Smith, Robert A, Bandi, Priti, Sauer, Ann Goding, Cotter, Megan, Sineshaw, Helmneh M, Jemal, Ahmedin, and Silvestri, Gerard A
- Subjects
LUNG cancer ,EARLY detection of cancer ,ADULTS ,TOMOGRAPHY ,CANCER patients - Abstract
Background: Annual lung cancer screening (LCS) with low-dose chest computed tomography in older current and former smokers (ie, eligible adults) has been recommended since 2013. Uptake has been slow and variable across the United States. We estimated the LCS rate and growth at the national and state level between 2016 and 2018.Methods: The American College of Radiology's Lung Cancer Screening Registry was used to capture screening events. Population-based surveys, the US Census, and cancer registry data were used to estimate the number of eligible adults and lung cancer mortality (ie, burden). Lung cancer screening rates (SRs) in eligible adults and screening rate ratios with 95% confidence intervals (CI) were used to measure changes by state and year.Results: Nationally, the SR was steady between 2016 (3.3%, 95% CI = 3.3% to 3.7%) and 2017 (3.4%, 95% CI = 3.4% to 3.9%), increasing to 5.0% (95% CI = 5.0% to 5.7%) in 2018 (2018 vs 2016 SR ratio = 1.52, 95% CI = 1.51 to 1.62). In 2018, several southern states with a high lung-cancer burden (eg, Mississippi, West Virginia, and Arkansas) had relatively low SRs (<4%) among eligible adults, whereas several northeastern states with lower lung cancer burden (eg, Massachusetts, Vermont, and New Hampshire) had the highest SRs (12.8%-15.2%). The exception was Kentucky, which had the nation's highest lung cancer mortality rate and one of the highest SRs (13.7%).Conclusions: Fewer than 1 in 20 eligible adults received LCS nationally, and uptake varied widely across states. LCS rates were not aligned with lung cancer burden across states, except for Kentucky, which has supported comprehensive efforts to implement LCS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States.
- Author
-
Osarogiagbon, Raymond U., Sineshaw, Helmneh M., Lin, Chun Chieh, and Jemal, Ahmedin
- Subjects
- *
LUNG cancer , *ONCOLOGIC surgery , *NON-small-cell lung carcinoma , *CANCER treatment , *POSTOPERATIVE care , *FIDUCIAL markers (Imaging systems) , *DATABASES , *RESEARCH , *KEY performance indicators (Management) , *RESEARCH methodology , *LUNG tumors , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *TUMOR classification , *COMPARATIVE studies , *CLINICAL medicine , *RESEARCH funding - Abstract
Background: Institutional-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC.Research Question: How do reversible differences in oncologic quality of care contribute to institutional-level disparities in early-stage NSCLC survival?Study Design and Methods: We retrospectively analyzed patients in the National Cancer Data Base who underwent NSCLC resection from 2004 through 2015 within institutions categorized as Community, Comprehensive Community, Integrated Network, Academic, and National Cancer Institute (NCI)-Designated Cancer Programs. We estimated percentages and adjusted ORs for six potentially avoidable poor-quality markers: incomplete resection, nonexamination of lymph nodes, nonanatomic resection, non-evidence-based use of adjuvant chemotherapy, non-evidence-based use of adjuvant radiation therapy, and 60-day postoperative mortality. By sequentially eliminating patients with poor-quality markers and calculating adjusted hazard ratios, we quantified their overall survival impact.Results: Of 169,775 patients, 7%, 46%, 10%, 24%, and 12% underwent surgery at Community, Comprehensive Community, Integrated Network, Academic, and NCI-Designated Cancer Programs, with 5-year overall survival rates of 52%, 56%, 58%, 60% and 66%, respectively. After the sequential elimination process, using NCI-Designated Cancer Centers as a reference, the adjusted hazard ratio for 5-year overall survival changed from 1.47 (95% CI, 1.41-1.53), 1.29 (95% CI, 1.25-1.33), 1.18 (95% CI, 1.14-1.23), and 1.20 (95% CI, 1.16-1.24) for Community, Comprehensive Community, Integrated Networks, and Academic Cancer Programs to 1.35 (95% CI, 1.28-1.42), 1.22 (95% CI, 1.17-1.26), 1.16 (95% CI, 1.11-1.22), and 1.17 (95% CI, 1.12-1.21), respectively (P < .001 for all comparisons with NCI-designated programs). Differences in quality of surgical resection and postoperative care accounted for 11% to 26% of the interinstitutional survival disparities.Interpretation: Targeting six readily identified poor-quality markers narrowed, but did not eliminate, institutional survival disparities. The greatest impact was in community programs. Residual factors driving persistent institution-level long-term NSCLC survival disparities must be characterized to eliminate them. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Factors Associated With Oncologist Discussions of the Costs of Genomic Testing and Related Treatments.
- Author
-
Yabroff, K Robin, Zhao, Jingxuan, Moor, Janet S de, Sineshaw, Helmneh M, Freedman, Andrew N, Zheng, Zhiyuan, Han, Xuesong, Rai, Ashish, Klabunde, Carrie N, and de Moor, Janet S
- Subjects
ONCOLOGISTS ,ELECTRONIC health records ,LOGISTIC regression analysis ,HEALTH insurance - Abstract
Background: Use of genomic testing is increasing in the United States. Testing can be expensive, and not all tests and related treatments are covered by health insurance. Little is known about how often oncologists discuss costs of testing and treatment or about the factors associated with those discussions.Methods: We identified 1220 oncologists who reported discussing genomic testing with their cancer patients from the 2017 National Survey of Precision Medicine in Cancer Treatment. Multivariable polytomous logistic regression analyses were used to assess associations between oncologist and practice characteristics and the frequency of cost discussions. All statistical tests were two-sided.Results: Among oncologists who discussed genomic testing with patients, 50.0% reported often discussing the likely costs of testing and related treatments, 26.3% reported sometimes discussing costs, and 23.7% reported never or rarely discussing costs. In adjusted analyses, oncologists with training in genomic testing or working in practices with electronic medical record alerts for genomic tests were more likely to have cost discussions sometimes (odds ratio [OR] = 2.09, 95% confidence interval [CI] = 1.19 to 3.69) or often (OR = 2.22, 95% CI = 1.30 to 3.79), respectively, compared to rarely or never. Other factors statistically significantly associated with more frequent cost discussions included treating solid tumors (rather than only hematological cancers), using next-generation sequencing gene panel tests, having higher patient volume, and working in practices with higher percentages of patients insured by Medicaid, or self-paid or uninsured.Conclusions: Interventions targeting modifiable oncologist and practice factors, such as training in genomic testing and use of electronic medical record alerts, may help improve cost discussions about genomic testing and related treatments. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Association of Medicaid Expansion Under the Affordable Care Act With Stage at Diagnosis and Time to Treatment Initiation for Patients With Head and Neck Squamous Cell Carcinoma.
- Author
-
Sineshaw, Helmneh M., Ellis, Mark A., Yabroff, K. Robin, Han, Xuesong, Jemal, Ahmedin, Day, Terry A., and Graboyes, Evan M.
- Published
- 2020
- Full Text
- View/download PDF
16. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States.
- Author
-
Freedman, Andrew N., Klabunde, Carrie N., Wiant, Kristine, Enewold, Lindsey, Gray, Stacy W., Filipski, Kelly K., Keating, Nancy L., Leonard, Debra G.b., Lively, Tracy, Mcneel, Timothy S., Minasian, Lori, Potosky, Arnold L., Rivera, Donna R., Schilsky, Richard L., Schrag, Deborah, Simonds, Naoko I., Sineshaw, Helmneh M., Struewing, Jeffery P., Willis, Gordon, and De Moor, Janet S.
- Subjects
CANCER treatment ,ONCOLOGISTS ,CANCER patients ,MEDICAL technology ,BIOINFORMATICS - Abstract
Purpose: There are no nationally representative data on oncologists' use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the United States use NGS tests to evaluate patients with cancer and to inform treatment recommendations. Methods: The study used data from the National Survey of Precision Medicine in Cancer Treatment, which was mailed to a nationally representative sample of oncologists in 2017 (N = 1,281; cooperation rate = 38%). Weighted percentages were calculated to describe NGS test use. Multivariable modeling was conducted to assess the association of test use with oncologist practice characteristics. Results: Overall, 75.6% of oncologists reported using NGS tests to guide treatment decisions. Of these oncologists, 34.0% used them often to guide treatment decisions for patients with advanced refractory disease, 29.1% to determine eligibility for clinical trials, and 17.5% to decide on off-label use of Food and Drug Administration–approved drugs. NGS test results informed treatment recommendations often for 26.8%, sometimes for 52.4%, and never or rarely for 20.8% of oncologists. Oncologists younger than 50 years of age, holding a faculty appointment, having genomics training, seeing more than 50 unique patients per month, and having access to a molecular tumor board were more likely to use NGS tests. Conclusion: In 2017, most oncologists in the United States were using NGS tests to guide treatment decisions for their patients. More research is needed to establish the clinical usefulness of these tests, to develop evidence-based clinical guidelines for their use in practice, and to ensure that patients who can benefit from these new technologies receive appropriate testing and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women.
- Author
-
Han, Xuesong, Zhao, Jingxuan, Ruddy, Kathryn J., Lin, Chun Chieh, Sineshaw, Helmneh M., and Jemal, Ahmedin
- Subjects
BREAST cancer treatment ,HEALTH insurance ,PATIENT Protection & Affordable Care Act ,CONTROL groups ,HEALTH policy - Abstract
Introduction: Breast cancer in young women tends to be more aggressive, but timely treatment may not be always available, particularly to those without health insurance. We aim to examine whether the dependent coverage expansion under the Affordable Care Act (ACA-DCE) implemented in 2010 was associated with changes in time to treatment among women diagnosed with early stage breast cancer. Methods: A total of 7,176 patients diagnosed with early stage breast cancer in 2007–2009 (pre-ACA) and 2011–2013 (post-ACA) were identified from the National Cancer Database. A quasi-experimental design difference-in-differences (DD) approach was used, with patients aged 19–25 (targeted by the policy) considered as the intervention group, and patients aged 26–34 years (not affected by the policy) as the control group. Changes in the following treatment outcomes were examined: time from diagnosis to surgery, time from surgery to adjuvant chemotherapy, and time from adjuvant chemotherapy to radiation. Results: Compared with the control group of patients aged 26–34, young patients aged 19–25 experienced a statistically nonsignificant decrease of 2.7 percentage points (95% CI [-1.2, 6.5]) in the uninsured rate. This did not translate into more reduction in delays to surgery (DD = 2.7 days, 95% CI [-3.2, 8.3]), chemotherapy (DD = -1.0 days, 95% CI [-7.2, 5.2]) or radiation (DD = 5.3 days, 95% CI [-15.6, 26.3]) in the younger cohort than the older cohort. Conclusions and Relevance: No significant changes in time to treatment were found among young women diagnosed with early stage breast cancer after the implementation of the ACA-DCE. Future studies examining impacts of health care policy reform on breast cancer care are warranted to include patients from low-income families and to consider effects from Medicaid expansion. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
- Author
-
Dominici, Laura S., Sineshaw, Helmneh M., Jemal, Ahmedin, Lin, Chun Chieh, King, Tari A., and Freedman, Rachel A.
- Abstract
Purpose: Although axillary lymph node status has traditionally been a key factor in informing adjuvant breast cancer therapy recommendations, this information may be less relevant as our focus shifts more towards tumor biology, particularly in older patients where comorbidity influences treatment decisions and nodal staging and/or surgery may not improve outcomes. We examined patterns of axillary surgery and associations between axillary surgery and receipt of adjuvant treatment in older breast cancer patients.Methods: Women aged ≥ 65 years with clinically node-negative, stage I–II breast cancer treated between 2012 and 2013 were identified using the National Cancer Data Base. Using multivariable logistic regression, we examined associations between axillary surgery and age, adjusting for patient, clinical, and facility factors. We also examined receipt of adjuvant treatment by nodal surgery.Results: Among 68,205 women, 40.1% were aged 65–70, 24.5% were 71–75, 17.4% were 76–80, and 18.0% were > 80. Overall, 91.2% had axillary surgery (67.8% sentinel lymph node biopsy, 11.7% axillary lymph node dissection, 11.7% unspecified/unknown axillary surgery); 88.0% of those aged ≥ 70 with lower risk, hormone receptor-positive tumors underwent axillary surgery. In adjusted analyses, compared to patients aged 65–70, increasing age was associated with lower odds of any axillary surgery (ages 71–75: OR 0.64, 95% CI 0.57–0.71; ages 76–80: OR 0.33, 95% CI 0.30–0.37; age > 80: OR 0.08, 95% CI 0.07–0.08). Axillary surgery was associated with higher odds of receipt of radiation after breast conservation and receipt of chemotherapy in human epidermal growth factor 2-positive disease.Conclusions: In a large nationwide dataset, the vast majority of older women with clinically node-negative breast cancer underwent axillary staging despite uncertainty about its impact on survival, particularly for those with lower-risk disease. Further study on how to tailor node assessment in older patients is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Contemporary Patterns and Survival Outcome of Adjuvant Systemic Therapy for Localized Gastrointestinal Stromal Tumors.
- Author
-
Sineshaw, Helmneh M., Jemal, Ahmedin, Chun Chieh Lin, McGinnis, LaMar S., and Ward, Elizabeth M.
- Published
- 2017
- Full Text
- View/download PDF
20. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival.
- Author
-
Mitin, Timur, Enestvedt, C. Kristian, Jemal, Ahmedin, and Sineshaw, Helmneh M.
- Subjects
GALLBLADDER cancer ,RADIOTHERAPY ,MEDICAL radiology ,PATIENT compliance ,HEALTH behavior ,COMBINED modality therapy ,GALLBLADDER tumors ,LONGITUDINAL method ,MULTIVARIATE analysis ,HEALTH outcome assessment ,LOGISTIC regression analysis ,PROPORTIONAL hazards models ,KAPLAN-Meier estimator - Abstract
Background: There are no randomized data to guide clinicians treating patients with gallbladder cancer (GBC). Several retrospective studies reported the survival benefits of adjuvant radiotherapy (RT) and chemoradiation (CRT). In this paper, we examine whether these publications have impacted the utilization of adjuvant therapies and whether their survival benefits are evident in a contemporary cohort of patients.Methods: Using the National Cancer Data Base, we identified 5029 patients diagnosed with T1-3N0-1 GBC and treated with surgical resection from 2005 to 2013. We described trends in receipt of adjuvant treatments for three time periods (2005-2007, 2008-2010, 2011-2013) and calculated three-year overall survival (OS) probabilities for 2989 patients treated in 2005-2010. All statistical tests were two-sided.Results: The percentage of patients who received no adjuvant treatments was unchanged from 2005 to 2013. Adjuvant RT decreased from 4.2% to 1.7% ( P < .001), adjuvant chemotherapy increased from 8.3% to 13.8% ( P < .001), and adjuvant CRT remained stable at 15.9% ( P = .98). Adjuvant treatments were associated with improved three-year OS, with adjusted hazard ratio of 0.47 (95% confidence interval [CI] = 0.39 to 0.58) for CRT, 0.77 (95% CI = 0.61 to 0.97) for chemotherapy, and 0.63 (95% CI = 0.44 to 0.92) for RT. Adjuvant CRT was associated with improved survival in all categories, except T1N0, and in patients with negative and positive margins.Conclusion: Over the past decade there was no increase in the utilization of adjuvant therapies in the United States for patients with resected GBC. Adjuvant therapy is associated with statistically significantly improved three-year OS. This analysis should form the basis for current clinical recommendations and support future prospective trials. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
21. Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base.
- Author
-
Sineshaw, Helmneh M., Jemal, Ahmedin, Thomas, Charles R., and Mitin, Timur
- Subjects
- *
RECTAL cancer treatment , *CHEMORADIOTHERAPY , *ADJUVANT treatment of cancer , *MEDICAL databases , *HEALTH outcome assessment , *SOCIOECONOMIC factors , *COMBINED modality therapy , *DATABASES , *SURVIVAL analysis (Biometry) , *DISEASE management , *TREATMENT effectiveness , *TUMOR treatment ,RECTUM tumors - Abstract
Background: In the United States, neoadjuvant chemoradiotherapy (NACRT) is widely accepted as the standard of care in the treatment of patients with locally advanced rectal cancer. In the current study, the authors attempted to examine patterns of treatment in the United States over the past decade.Methods: Using the National Cancer Data Base, a total of 66,197 patients who were diagnosed with American Joint Committee on Cancer stage II to III rectal adenocarcinoma and treated between 2004 and 2012 were identified. The authors described trends in the receipt of treatment for 3 time periods (2004-2006, 2007-2009, and 2010-2012) and analyzed 5-year overall survival probabilities for 28,550 patients treated between 2004 and 2007.Results: Receipt of NACRT increased significantly from 42.9% between 2004 and 2006 to 50.0% between 2007 and 2009, and to 55.0% between 2010 and 2012 (P < .0001). In contrast, the use of adjuvant chemoradiotherapy (CRT) decreased from 16.7% between 2004 and 2006 to 10.5% between 2007 and 2009, and to 6.7% between 2010 and 2012 (P < .0001). Similarly, the use of surgery alone decreased from 13.1% between 2004 and 2006 to 8.7% between 2010 and 2012 (P < .0001). Older age, the presence of comorbidities, larger primary tumor size, lymph node involvement, not being of non-Hispanic white race/ethnicity, lack of private insurance, and treatment at a facility that did not have a high case volume were associated with a significantly lower possibility of receiving NACRT. The 5-year overall survival rates for patients treated with NACRT, surgery and adjuvant CRT, surgery alone, and definitive CRT were 72.4%, 70.9%, 44.9%, and 48.8%, respectively.Conclusions: The use of NACRT before surgery in US patients with rectal cancer has substantially increased over the past decade. However, only approximately one-half of patients currently receive this standard therapy, which could be explained in part by socioeconomic factors. Trimodality therapy is associated with the best outcomes for these patients. Cancer 2016;122:1996-2003. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
22. Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base.
- Author
-
Sineshaw, Helmneh M., Gray, Phillip J., Efstathiou, Jason A., and Jemal, Ahmedin
- Subjects
- *
PROSTATECTOMY , *PROSTATE cancer treatment , *PROSTATE cancer patients , *CANCER radiotherapy , *MEDICAL databases , *CLINICAL trials , *HEALTH outcome assessment - Abstract
Background Patterns of postoperative radiotherapy (RT) use in prostate cancer (PCa) after the publication of major randomized trials have not been well characterized. Objective To describe patterns of postoperative RT use after radical prostatectomy (RP) in patients with adverse pathologic features in the United States. Design, setting, and participants Retrospective analysis of 97 270 patients with PCa diagnosed between 2005 and 2011 whose presentation and outcomes were recorded in the National Cancer Data Base. Outcome measurements and statistical analysis Temporal changes in receipt of postoperative RT and factors associated with receipt of this treatment using the Cochran–Armitage trend test and multiple logistic regression, respectively. Results and limitations Between 2005 and 2011, receipt of postoperative RT decreased steadily from 9.1% to 7.3% ( p trend < 0.001). Use of RT with or without androgen deprivation therapy monotonically decreased with advancing age from 8.5% in patients aged 18–59 yr to 6.8% in patients aged 70–79 yr ( p trend < 0.001). Receipt of RT was higher at community cancer programs compared with teaching/research centers (14% vs 7.3%; odds ratio [OR]: 2.16; p < 0.001), in those with pT3-4 disease and positive margins compared with those with pT3-4 and negative margins (17% vs 5.9%; OR: 2.89; p < 0.001), and in patients with a Gleason score of 8–10 compared with those with a Gleason score of 2–6 (17% vs 4.2%; OR: 3.50; p < 0.001). Limitations include lack of postprostatectomy prostate-specific antigen level. Conclusions Postoperative RT use for localized PCa in patients with adverse pathologic features is declining in the United States. Patient summary In this report, we show that use of postoperative radiotherapy in patients with prostate cancer with adverse pathologic features is declining. Patients treated at community cancer programs, those with locally advanced disease and positive margins, and those with a high Gleason score were more likely to receive postoperative radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Black/White Disparities in Receipt of Treatment and Survival Among Men With Early-Stage Breast Cancer.
- Author
-
Sineshaw, Helmneh M., Freedman, Rachel A., Ward, Elizabeth M., Flanders, W. Dana, and Jemal, Ahmedin
- Published
- 2015
- Full Text
- View/download PDF
24. Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018.
- Author
-
Nogueira, Leticia M., Sineshaw, Helmneh M., Jemal, Ahmedin, Pollack, Craig E., Efstathiou, Jason A., and Yabroff, K. Robin
- Published
- 2022
- Full Text
- View/download PDF
25. Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis.
- Author
-
Sineshaw, Helmneh M, Jemal, Ahmedin, Ng, Kimmie, Osarogiagbon, Raymond U, Yabroff, K Robin, Ruddy, Kathryn J, and Freedman, Rachel A
- Subjects
CANCER treatment ,METASTASIS ,COLON cancer ,PANCREATIC cancer ,LUNG cancer ,CANCER chemotherapy ,ONCOLOGIC surgery - Abstract
Background Little is known about patterns of and factors associated with treatment for de novo metastatic cancer patients who die soon after diagnosis. In this study, we examine treatment patterns for patients newly diagnosed with metastatic lung, colorectal, breast, or pancreatic cancer who died within 1 month of diagnosis. Methods We identified 100 848 adult patients in the National Cancer Database with de novo metastatic lung, colorectal, breast, and pancreatic cancer, diagnosed between 2004 and 2014 and who died within 1 month. We performed descriptive and multivariable logistic regression analyses to examine receipt of surgery, chemotherapy, radiation, and hormonal therapy by cancer type, adjusting for sociodemographic and clinical variables. Results Treatment substantially varied by cancer type, over time, age, insurance, and facility type. Surgery ranged from 0.4% in pancreatic to 28.3% in colorectal cancer (CRC) patients, chemotherapy from 5.8% among CRC to 11% in lung and breast cancer patients, and radiotherapy from 1.3% in pancreatic to 18.7% in lung cancer patients. Use of some treatments (eg, surgery for CRC and breast cancer) progressively declined between 2004 and 2014. Compared with lung cancer patients treated at National Cancer Institute-designated cancer centers, those treated at community cancer centers had 48% lower odds of radiation. Conclusions Treatment of patients diagnosed with imminently fatal de novo metastatic cancer varied markedly by cancer type and patient/facility characteristics. These variations warrant more research to better identify patients with imminently fatal de novo metastatic cancer who may not benefit from aggressive and expensive therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States.
- Author
-
Fedewa SA, Kazerooni EA, Studts JL, Smith RA, Bandi P, Sauer AG, Cotter M, Sineshaw HM, Jemal A, and Silvestri GA
- Subjects
- Adult, Aged, Educational Status, Humans, Mass Screening methods, Tomography, X-Ray Computed methods, United States epidemiology, Early Detection of Cancer, Lung Neoplasms diagnostic imaging, Lung Neoplasms epidemiology
- Abstract
Background: Annual lung cancer screening (LCS) with low-dose chest computed tomography in older current and former smokers (ie, eligible adults) has been recommended since 2013. Uptake has been slow and variable across the United States. We estimated the LCS rate and growth at the national and state level between 2016 and 2018., Methods: The American College of Radiology's Lung Cancer Screening Registry was used to capture screening events. Population-based surveys, the US Census, and cancer registry data were used to estimate the number of eligible adults and lung cancer mortality (ie, burden). Lung cancer screening rates (SRs) in eligible adults and screening rate ratios with 95% confidence intervals (CI) were used to measure changes by state and year., Results: Nationally, the SR was steady between 2016 (3.3%, 95% CI = 3.3% to 3.7%) and 2017 (3.4%, 95% CI = 3.4% to 3.9%), increasing to 5.0% (95% CI = 5.0% to 5.7%) in 2018 (2018 vs 2016 SR ratio = 1.52, 95% CI = 1.51 to 1.62). In 2018, several southern states with a high lung-cancer burden (eg, Mississippi, West Virginia, and Arkansas) had relatively low SRs (<4%) among eligible adults, whereas several northeastern states with lower lung cancer burden (eg, Massachusetts, Vermont, and New Hampshire) had the highest SRs (12.8%-15.2%). The exception was Kentucky, which had the nation's highest lung cancer mortality rate and one of the highest SRs (13.7%)., Conclusions: Fewer than 1 in 20 eligible adults received LCS nationally, and uptake varied widely across states. LCS rates were not aligned with lung cancer burden across states, except for Kentucky, which has supported comprehensive efforts to implement LCS., (© The Author(s) 2020. Published by Oxford University Press.)
- Published
- 2021
- Full Text
- View/download PDF
27. Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes.
- Author
-
Osarogiagbon RU, Sineshaw HM, Unger JM, Acuña-Villaorduña A, and Goel S
- Subjects
- Healthcare Disparities, Humans, Immunotherapy, Minority Groups, Patient Protection and Affordable Care Act, United States epidemiology, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Avoidable differences in the care and outcomes of patients with cancer (i.e., cancer care disparities) emerge or worsen with discoveries of new, more effective approaches to cancer diagnosis and treatment. The rapidly expanding use of immunotherapy for many different cancers across the spectrum from late to early stages has, predictably, been followed by emerging evidence of disparities in access to these highly effective but expensive treatments. The danger that these new treatments will further widen preexisting cancer care and outcome disparities requires urgent corrective intervention. Using a multilevel etiologic framework that categorizes the targets of intervention at the individual, provider, health care system, and social policy levels, we discuss options for a comprehensive approach to prevent and, where necessary, eliminate disparities in access to the clinical trials that are defining the optimal use of immunotherapy for cancer, as well as its safe use in routine care among appropriately diverse populations. We make the case that, contrary to the traditional focus on the individual level in descriptive reports of health care disparities, there is sequentially greater leverage at the provider, health care system, and social policy levels to overcome the challenge of cancer care and outcomes disparities, including access to immunotherapy. We also cite examples of effective government-sponsored and policy-level interventions, such as the National Cancer Institute Minority-Underserved Community Oncology Research Program and the Affordable Care Act, that have expanded clinical trial access and access to high-quality cancer care in general.
- Published
- 2021
- Full Text
- View/download PDF
28. Factors Associated With Oncologist Discussions of the Costs of Genomic Testing and Related Treatments.
- Author
-
Yabroff KR, Zhao J, de Moor JS, Sineshaw HM, Freedman AN, Zheng Z, Han X, Rai A, and Klabunde CN
- Subjects
- Adult, Female, Genetic Testing economics, Humans, Male, Medical Oncology methods, Middle Aged, Neoplasms economics, Neoplasms genetics, Oncologists psychology, Oncologists statistics & numerical data, Surveys and Questionnaires, United States, Communication, Genomics economics, Medical Oncology economics, Physician-Patient Relations
- Abstract
Background: Use of genomic testing is increasing in the United States. Testing can be expensive, and not all tests and related treatments are covered by health insurance. Little is known about how often oncologists discuss costs of testing and treatment or about the factors associated with those discussions., Methods: We identified 1220 oncologists who reported discussing genomic testing with their cancer patients from the 2017 National Survey of Precision Medicine in Cancer Treatment. Multivariable polytomous logistic regression analyses were used to assess associations between oncologist and practice characteristics and the frequency of cost discussions. All statistical tests were two-sided., Results: Among oncologists who discussed genomic testing with patients, 50.0% reported often discussing the likely costs of testing and related treatments, 26.3% reported sometimes discussing costs, and 23.7% reported never or rarely discussing costs. In adjusted analyses, oncologists with training in genomic testing or working in practices with electronic medical record alerts for genomic tests were more likely to have cost discussions sometimes (odds ratio [OR] = 2.09, 95% confidence interval [CI] = 1.19 to 3.69) or often (OR = 2.22, 95% CI = 1.30 to 3.79), respectively, compared to rarely or never. Other factors statistically significantly associated with more frequent cost discussions included treating solid tumors (rather than only hematological cancers), using next-generation sequencing gene panel tests, having higher patient volume, and working in practices with higher percentages of patients insured by Medicaid, or self-paid or uninsured., Conclusions: Interventions targeting modifiable oncologist and practice factors, such as training in genomic testing and use of electronic medical record alerts, may help improve cost discussions about genomic testing and related treatments., (Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.)
- Published
- 2020
- Full Text
- View/download PDF
29. Early Postoperative Mortality Among Patients Aged 75 Years or Older With Stage II/III Rectal Cancer.
- Author
-
Sineshaw HM, Yabroff KR, Tsikitis VL, Jemal A, and Mitin T
- Subjects
- Age Factors, Aged, Aged, 80 and over, Comorbidity, Factor Analysis, Statistical, Female, Humans, Mortality, Neoplasm Staging, Odds Ratio, Outcome Assessment, Health Care, Postoperative Complications etiology, Rectal Neoplasms mortality, Rectal Neoplasms pathology, Rectal Neoplasms surgery, Registries, Time Factors, Postoperative Complications epidemiology, Rectal Neoplasms epidemiology
- Abstract
Background: Elderly patients with rectal cancer have been excluded from randomized studies, thus little is known about their early postoperative mortality, which is critical for informed consent and treatment decisions. This study examined early mortality after surgery in elderly patients with locally advanced rectal cancer (LARC)., Methods: Using the National Cancer Database, we identified patients aged ≥75 years, diagnosed with clinical stage II/III rectal cancer who underwent surgery in 2004 through 2015. Descriptive analyses determined proportions and trends and multivariable logistic regression analyses were performed to determine factors associated with early mortality after rectal cancer surgery., Results: Among 11,794 patients with rectal cancer aged ≥75 years, approximately 6% underwent local excision and 94% received radical resection. Overall 30-day, 90-day, and 6-month postoperative mortality rates were 4.2%, 7.8%, and 11.5%, respectively. Six-month mortality varied by age (8.4% in age 75-79 years to 18.3% in age ≥85 years), and comorbidity score (10.1% for comorbidity score 0 to 17.7% for comorbidity score ≥2). Six-month mortality declined from 12.3% in 2004 through 2007 to 10.2% in 2012 through 2015 (Ptrend=.0035). Older age, higher comorbidity score, and lower facility case volume were associated with higher 6-month mortality. Patients treated at NCI-designated centers had 30% lower odds of 6-month mortality compared with those treated at teaching/research centers., Conclusions: Six-month mortality rates after surgery among patients aged ≥75 years with LARC have declined steadily over the past decade in the United States. Older age, higher comorbidity score, and care at a low-case-volume facility were associated with higher 6-month mortality after surgery. This information is necessary for informed consent and decisions regarding optimal management of elderly patients with LARC.
- Published
- 2020
- Full Text
- View/download PDF
30. Association of Medicaid Expansion Under the Affordable Care Act With Stage at Diagnosis and Time to Treatment Initiation for Patients With Head and Neck Squamous Cell Carcinoma.
- Author
-
Sineshaw HM, Ellis MA, Yabroff KR, Han X, Jemal A, Day TA, and Graboyes EM
- Subjects
- Adolescent, Adult, Female, Humans, Insurance Coverage, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Time-to-Treatment, United States, Young Adult, Head and Neck Neoplasms pathology, Head and Neck Neoplasms therapy, Medicaid organization & administration, Patient Protection and Affordable Care Act, Squamous Cell Carcinoma of Head and Neck pathology, Squamous Cell Carcinoma of Head and Neck therapy
- Abstract
Importance: Medicaid expansions as part of the Patient Protection and Affordable Care Act (ACA) are associated with decreases in the percentage of uninsured patients who have received a new diagnosis of cancer. Little is known about the association of Medicaid expansions with stage at diagnosis and time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC)., Objective: To determine the association of Medicaid expansions as part of the ACA with stage at diagnosis and TTI for patients with HNSCC., Design, Setting, and Participants: A retrospective cohort study was conducted at Commission on Cancer-accredited facilities among 90 789 patients identified from the National Cancer Database aged 18 to 64 years with HNSCC that was diagnosed during the period from January 1, 2010, to December 31, 2016. Statistical analysis was conducted from February 18 to November 8, 2019., Main Outcomes and Measures: Outcome measures included health insurance coverage, stage at diagnosis, and TTI. Absolute percentage change in health insurance coverage, crude and adjusted difference in differences (DD) in absolute percentage change in coverage, stage at diagnosis, and TTI before (2010-2013) and after (2014-2016) ACA implementation were calculated for Medicaid expansion and nonexpansion states., Results: Of the 90 789 nonelderly adults with newly diagnosed HNSCC (mean [SD] age, 54.7 [7.0] years), 70 907 (78.1%) were men, 72 911 (80.3%) were non-Hispanic white, 52 142 (57.4%) were between 55 and 64 years of age, and 54 940 (60.5%) resided in states with an ACA Medicaid expansion. Compared with nonexpansion states, the percentage of patients with HNSCC with Medicaid increased more in expansion states after the implementation of the ACA (adjusted DD, 4.6 percentage points [95% CI, 3.7-5.4 percentage points]). The percentage of patients with localized disease (American Joint Committee on Cancer stage I-II) at diagnosis increased in expansion states compared with nonexpansion states for the overall cohort (adjusted DD, 2.3 percentage points [95% CI, 1.1-3.5 percentage points]) and for the subset of patients with nonoropharyngeal HNSCC (adjusted DD, 3.4 percentage points [95% CI, 1.5-5.2 percentage points]). The mean TTI did not differ between expansion and nonexpansion states for the cohort (adjusted DD, -12.7 percentage points [95% CI, -27.4 to 4.2 percentage points]) but improved for patients with nonoropharyngeal HNSCC (adjusted DD, -26.5 percentage points [95% CI, -49.6 to -3.4 percentage points])., Conclusions and Relevance: This study suggests that Medicaid expansions were associated with a greater increase in the percentage of patients with HNSCC with Medicaid coverage, an increase in the percentage of patients with localized disease at diagnosis for the overall cohort of patients with HNSCC, and improved TTI for patients with nonoropharyngeal HNSCC.
- Published
- 2020
- Full Text
- View/download PDF
31. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival.
- Author
-
Mitin T, Enestvedt CK, Jemal A, and Sineshaw HM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Adjuvant statistics & numerical data, Chemoradiotherapy, Adjuvant trends, Chemotherapy, Adjuvant statistics & numerical data, Chemotherapy, Adjuvant trends, Female, Follow-Up Studies, Gallbladder Neoplasms surgery, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Radiotherapy, Adjuvant statistics & numerical data, Radiotherapy, Adjuvant trends, United States, Young Adult, Gallbladder Neoplasms drug therapy, Gallbladder Neoplasms radiotherapy, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data
- Abstract
Background: There are no randomized data to guide clinicians treating patients with gallbladder cancer (GBC). Several retrospective studies reported the survival benefits of adjuvant radiotherapy (RT) and chemoradiation (CRT). In this paper, we examine whether these publications have impacted the utilization of adjuvant therapies and whether their survival benefits are evident in a contemporary cohort of patients., Methods: Using the National Cancer Data Base, we identified 5029 patients diagnosed with T1-3N0-1 GBC and treated with surgical resection from 2005 to 2013. We described trends in receipt of adjuvant treatments for three time periods (2005-2007, 2008-2010, 2011-2013) and calculated three-year overall survival (OS) probabilities for 2989 patients treated in 2005-2010. All statistical tests were two-sided., Results: The percentage of patients who received no adjuvant treatments was unchanged from 2005 to 2013. Adjuvant RT decreased from 4.2% to 1.7% ( P < .001), adjuvant chemotherapy increased from 8.3% to 13.8% ( P < .001), and adjuvant CRT remained stable at 15.9% ( P = .98). Adjuvant treatments were associated with improved three-year OS, with adjusted hazard ratio of 0.47 (95% confidence interval [CI] = 0.39 to 0.58) for CRT, 0.77 (95% CI = 0.61 to 0.97) for chemotherapy, and 0.63 (95% CI = 0.44 to 0.92) for RT. Adjuvant CRT was associated with improved survival in all categories, except T1N0, and in patients with negative and positive margins., Conclusion: Over the past decade there was no increase in the utilization of adjuvant therapies in the United States for patients with resected GBC. Adjuvant therapy is associated with statistically significantly improved three-year OS. This analysis should form the basis for current clinical recommendations and support future prospective trials., (© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.